We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Cingulate Inc | NASDAQ:CINGW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0001 | 0.83% | 0.0122 | 0.0121 | 0.0299 | 0.0122 | 0.0122 | 0.0122 | 200 | 21:00:02 |
Cingulate Chairman & CEO Shane J. Schaffer is scheduled to present a company overview on June 6th at 9:30 a.m. PST. A webcast of the presentation will be available on the investors section of Cingulate’s corporate site at www.cingulate.com.
Cingulate’s lead Phase 3 candidate, CTx-1301, is a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD). In addition to the Company’s initial focus on the $22bn ADHD market, Cingulate is identifying other indications, such as anxiety, where it’s PTR™ technology may be effectively utilized.
To arrange a meeting with Cingulate, please contact your LD Micro representative, or Cingulate investor relations at mkreps@darrowir.com.
About Cingulate®Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary PTR™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.
Investor Contact:Thomas DaltonVice President, Investor & Public Relations, Cingulate913-942-2301TDalton@cingulate.com
Matt KrepsDarrow Associates Investor Relations214-597-8200mkreps@darrowir.com
1 Year Cingulate Chart |
1 Month Cingulate Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions